Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials
Two key factors predicted higher likelihood of meeting endpoints: younger patient age and primary endpoints other than OS. Although head-to-head design is considered riskier, it was not associated with decreased success. This analysis aims to better inform clinicians, industry, and regulators in myeloma drug development.
Authors
- Oliver Van Oekelen (ORCID: https://orcid.org/0000-0002-5824-197X)
- Rajshekhar Chakraborty (ORCID: https://orcid.org/0000-0001-7336-3003)
- Ghulam Rehman Mohyuddin (ORCID: https://orcid.org/0000-0001-6464-783X)
- Anikó Szabó (ORCID: https://orcid.org/0000-0002-8129-0614)
- Samer Al Hadidi (ORCID: https://orcid.org/0000-0003-4297-8042)
- Hira S. Mian (ORCID: https://orcid.org/0000-0003-1584-1067)
- Meera Mohan (ORCID: https://orcid.org/0000-0002-6913-6526)
- Maria Mainou (ORCID: https://orcid.org/0000-0002-5775-2241)
- Alissa Visram (ORCID: https://orcid.org/0000-0002-7201-4642)
- K. Elias (ORCID: https://orcid.org/0000-0002-6226-1252)
- Rakesh Popat (ORCID: https://orcid.org/0000-0001-6553-4618)
- Edward R. Scheffer Cliff (ORCID: https://orcid.org/0000-0001-5977-907X)
- Kalliopi Tsapa
- Muatassem Alsadhan
Institutions
- Brigham and Women's Hospital (US)
- The Royal Melbourne Hospital (AU)
- The University of Melbourne (AU)
- Medical College of Wisconsin (US)
- Aristotle University of Thessaloniki (GR)
- Heidelberg University (DE)
- Columbia University Irving Medical Center (US)
- Peter MacCallum Cancer Centre (AU)
- Huntsman Cancer Institute (US)
- University Hospital Heidelberg (DE)
- Southwestern Medical Center (US)
- The London College (GB)
- University College London (GB)
- The University of Texas Southwestern Medical Center (US)
- McMaster University (CA)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2025-11-09
- DOI
- https://doi.org/10.1093/jnci/djaf326
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00